Wang L, et al. - This trial examined the efficacy of a FISH assay to screen for BRAF gene rearrangements in pancreatic acinar-type neoplasms. The FISH assay appeared to be highly sensitive and specific along with being time- and cost-efficient in the detection of BRAF fusions in acinar-type neoplasms, than the targeted next-generation sequencing-based technologies. It could be readily implemented in diagnostic settings to determine acinar-type neoplasms patients potentially, who would be suitable for targeted therapy to inhibit MAPK pathway activity.